共 302 条
[1]
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249
[2]
Ferlay J(2018)The biology and management of non-small cell lung cancer Nature 553 446-454
[3]
Siegel RL(2021)Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC Nat Rev Clin Oncol 18 625-644
[4]
Laversanne M(2018)Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries Lancet Glob Health 6 e555-e567
[5]
Soerjomataram I(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542-2550
[6]
Jemal A(2015)BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer J Clin Oncol 33 2197-2204
[7]
Bray F(2018)Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) Br J Cancer 118 654-661
[8]
Herbst RS(2018)Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial JAMA Oncol 4 1569-1575
[9]
Morgensztern D(2020)Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study Ther Adv Med Oncol 12 1758835920968472-5457
[10]
Boshoff C(2019)The Intersection between Tumor Angiogenesis and Immune Suppression Clin Cancer Res 25 5449-203